All Stories

  1. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
  2. Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress
  3. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
  4. Neuroprogression in anxiety disorders
  5. Anxiety Disorders
  6. The role of spatial store and executive strategy in spatial working memory: a comparison between patients with obsessive–compulsive disorder and controls
  7. Controlled-release pregabalin in the treatment of fibromyalgia
  8. Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years
  9. Commentary: Cognitive Behavioral Therapy vs. Eye Movement Desensitization and Reprocessing for Treating Panic Disorder: A Randomized Controlled Trial
  10. Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review
  11. The key role of body and its control mechanisms in Panic Disorder
  12. A focus on the adverse effects of clozapine
  13. A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer’s Disease Conversion in Individuals with Mild and Premild Cognitive Impairment
  14. Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective
  15. Mental health professionals’ attitudes towards mental illness: professional and cultural factors in the INTER NOS study
  16. Personality biomarkers of pathological gambling: A machine learning study
  17. Features of mood associated with high body weight in females with fibromyalgia
  18. Reduced cortical thickness and increased gyrification in generalized anxiety disorder: a 3 T MRI study
  19. Does gender influence cognitive function in non-psychotic depression?
  20. Precision Psychiatry: Personalized Clinical Approach to Depression
  21. Management of Treatment-Resistant Panic Disorder
  22. The revolution of personalized psychiatry: will technology make it happen sooner?
  23. Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review
  24. The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions
  25. Personalized Medicine in Psychiatry: Back to the Future
  26. Personalized medicine in panic disorder: where are we now? A meta-regression analysis
  27. The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review
  28. Current and Future Perspectives on the Major Depressive Disorder: Focus on Vortioxetine
  29. Short-Term Psychiatric Rehabilitation in Major Depressive and Bipolar Disorders: Neuropsychological-Psychosocial Outcomes
  30. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
  31. Does the “” Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients
  32. Latent classes of emotional and behavioural problems in epidemiological and referred samples and their relations to DSM-IV diagnoses
  33. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders
  34. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
  35. Does neuropsychological performance impact on real-life functional achievements in obsessive-compulsive disorder? A preliminary study
  36. Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates
  37. Mediation effect of recent loss events on weight gain in obese people who experienced childhood parental death or separation
  38. Inflammatory markers and suicidal attempts in depressed patients: A review
  39. An update of safety of clinically used atypical antipsychotics
  40. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials
  41. Role of worry in patients with chronic tinnitus and sensorineural hearing loss: a preliminary study
  42. Comments on “Heart rate and respiratory response to doxapram in patients with panic disorder”
  43. The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis
  44. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine
  45. Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines
  46. Is there cardiac risk in panic disorder? An updated systematic review
  47. Bipolar Polypharmacy
  48. Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials
  49. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review
  50. A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.
  51. Different Effects of Cigarette Smoking on Neuropsychological Performance in Psychiatric Disorders
  52. Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression
  53. Effect of family structure and TPH2 G-703T on the stability of dysregulation profile throughout adolescence
  54. The HPA axis in bipolar disorder: Systematic review and meta-analysis
  55. Panic Disorder, Is It Really a Mental Disorder? From Body Functions to the Homeostatic Brain
  56. The role of melatonin in mood disorders
  57. Psychiatric Disorders and Childhood Parental Loss in Obesity: Relationship with the Mode of Weight Gain
  58. Is there a role for pharmacogenetics in the treatment of panic disorder?
  59. Effects of Public Awareness and Stigmatization on Accurate and Timely Diagnosis of Bipolar Disorder
  60. Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2)
  61. Laboratory, Clinical and Therapeutic Features of Respiratory Panic Disorder Subtype
  62. Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder
  63. Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: An exploratory study
  64. Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
  65. Prevalence and clinical features associated to bipolar disorder–migraine comorbidity: a systematic review
  66. Novel investigational therapeutics for panic disorder
  67. Melatonergic Antidepressant Agomelatine in Depressive and Anxiety Disorders
  68. Childhood Trauma, Temperament, and Character in Subjects With Major Depressive Disorder and Bipolar Disorder
  69. Panic and the Brainstem: Clues from Neuroimaging Studies
  70. Alexithymia, suicidal ideation, and serum lipid levels among drug-naïve outpatients with obsessive-compulsive disorder
  71. Self-reported quality of life and clinician-rated functioning in mood and anxiety disorders: Relationships and neuropsychological correlates
  72. Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
  73. Cotard’s Syndrome: Clinical Case Presentation and Literature Review
  74. Are Respiratory Abnormalities Specific for Panic Disorder? A Meta-Analysis
  75. Insomnia as a predictor of high-lethality suicide attempts
  76. Effect of the serotonin transporter gene and of environment on the continuity of anxiety and depression traits throughout adolescence
  77. Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review
  78. The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
  79. Baseline respiratory parameters in panic disorder: A meta-analysis
  80. Urinary incontinence and diarrhoea associated with the switch from oral to injectable risperidone
  81. Effects of Cigarette Smoking on Neuropsychological Performance in Mood Disorders
  82. S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study
  83. The somatic marker affecting decisional processes in obsessive-compulsive disorder
  84. Temperament, Character and Anxiety Sensitivity in Panic Disorder: A High-Risk Study
  85. The Relationships between Cholesterol and Suicide: An Update
  86. The “Emotional Side” of Subjective Tinnitus
  87. Cardiorespiratory response to physical exercise and psychological variables in panic disorder
  88. Emerging drugs for panic disorder
  89. Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition
  90. Is there a hypersensitive visual alarm system in panic disorder?
  91. Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines
  92. Panic Disorder Respiratory Subtype: Psychopathology, Laboratory Challenge Tests, and Response to Treatment
  93. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature
  94. Acoustic startle response in panic disorder
  95. Tradução e adaptação transcultural do Questionário de Atividade Física Habitual
  96. Carbon dioxide-induced panic attacks and quantitative electroencephalogram in panic disorder patients
  97. Dizziness, migrainous vertigo and psychiatric disorders
  98. Freezing reaction in panic disorder patients associated with anticipatory anxiety
  99. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders
  100. Clonazepam in the treatment of psychiatric disorders: an update
  101. Antipanic Efficacy of Paroxetine and Polymorphism within the Promoter of the Serotonin Transporter Gene
  102. Anxiety Sensitivity in Children of Panic Disorder Patients
  103. Smoking and respiratory irregularity in panic disorder
  104. Comparison of the Treatment with Paroxetine and Reboxetine in Panic Disorder: A Randomized, Single-Blind Study
  105. Modulation of Hyperreactivity to 35% CO2 After One Week of Treatment With Paroxetine and Reboxetine
  106. Panic disorder: from respiration to the homeostatic brain
  107. Comparison of 35% carbon dioxide reactivity between panic disorder and eating disorder
  108. Anxiety sensitivity and modulation of the serotonergic system in patients with PD
  109. Approximate Entropy of Respiratory Patterns in Panic Disorder
  110. Language of dyspnea in panic disorder
  111. Selective serotonin re-uptake inhibitors beyond psychiatry: Are they useful in the treatment of severe, chronic, obstructive pulmonary disease?
  112. Lack of relationship between CO2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder
  113. Vulnerability to 35% CO2 of panic disorder patients with a history of respiratory disorders
  114. Pregnancy and Respiratory Nocturnal Panic Attacks
  115. Anxiety sensitivity and 35% CO2 reactivity in patients with panic disorder
  116. Neurosteroid secretion in panic disorder
  117. The Effect of One-Week Treatment with Venlafaxine on 35% CO2 Hyperreactivity in Patients with Panic Disorder: An Open Study
  118. Serotonergic modulation of the balance system in panic disorder: An open study
  119. Antipanic Drug Modulation Of 35% CO2 Hyperreactivity and Short-Term Treatment Outcome
  120. Respiration in Children at Risk for Panic Disorder
  121. Panic disorder: the role of the balance system
  122. The 35% CO 2 Hyperreactivity and Clinical Symptomatology in Patients With Panic Disorder After 1 Week of Treatment With Citalopram: An Open Study
  123. A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study
  124. Dopamine function in obsessive compulsive disorder: cortisol response to acute apomorphine stimulation
  125. Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy
  126. A segregation study of panic disorder in families of panic patients responsive to the 35% CO2 challenge
  127. Sensitivity to 35% Carbon Dioxide in Patients With Generalized Anxiety Disorder
  128. A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO2 challenge
  129. Growth hormone response to growth hormone-releasing hormone stimulation in obsessive–compulsive disorder
  130. CO 2 -Induced Panic Attacks: A Twin Study
  131. PLASMA CONCENTRATIONS OF INTERLEUKIN-1β, INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR-α IN ANOREXIA AND BULIMIA NERVOSA
  132. Plasma Interleukin-1β and Tumor Necrosis Factor Concentrations in Obsessive–Compulsive Disorders
  133. Dopamine function in obsessive—compulsive disorder: Growth hormone response to apomorphine stimulation
  134. Asthma and panic attacks
  135. Anxiety sensitivity and 35% CO2 reactivity in panic patients
  136. Modification of 35% Carbon Dioxide Hypersensitivity Across One Week of Treatment With Clomipramine and Fluvoxamine
  137. The 35% CO2 challenge test in patients with social phobia
  138. Pharmacologic Effect of Imipramine, Paroxetine, and Sertraline on 35% Carbon Dioxide Hypersensitivity in Panic Patients
  139. Noradrenergic receptor sensitivity in obsessive-compulsive disorders: I. growth hormone response to clonidine stimulation
  140. Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration
  141. Panic attacks: a twin study
  142. Citalopram and panic disorder
  143. Citalopram and panic disorder
  144. T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa
  145. T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa
  146. Hypersensitivity to inhalation of carbon dioxide and panic attacks
  147. Menstrual cycle-related sensitivity to 35% CO2 in panic patients
  148. The 35% CO2 challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis
  149. 35% CO2 challenge in panic and mood disorders
  150. α2-Adrenergic receptor sensitivity in panic disorder: II
  151. α2-Adrenergic receptor sensitivity in panic disorder: I
  152. Pharmacologic Effect of Toloxatone on Reactivity to the 35% Carbon Dioxide Challenge
  153. Subclinical impairment of lung airways in patients with panic disorder
  154. Plasma interleukin-1 beta concentrations in panic disorder
  155. Carbon dioxide/oxygen challenge test in panic disorder
  156. Prevalence of respiratory diseases in patients with panic and obsessive compulsive disorders
  157. Alpha-2-Adrenoceptor Sensitivity in Heroin Addicts with and without Previous Attention Deficit Disorder/Hyperactivity and Conduct Disorder
  158. DSM-III-R personality disorders in panic disorder
  159. Psychoimmunoendocrine Aspects of Panic Disorder
  160. DSM-III-R personality disorders in panic and obsessive-compulsive disorder: A comparison study
  161. Anxiety, depression, and suicide: epidemiology, pathophysiology, and prevention
  162. Respiration and Anxiety